BioCardia, Inc.: directors' dealings · United States · SEC (Form 4)

About BioCardia, Inc.

BioCardia, Inc. (ticker: BCDA) is a U.S.-based biotechnology company listed on the NASDAQ in the United States, focused on cell therapies and related delivery systems for cardiovascular and pulmonary diseases with substantial unmet medical need. Headquartered in Sunnyvale, California, the company operates in a single business segment and is best described as a clinical-stage regenerative medicine platform rather than a commercial pharmaceutical manufacturer. Its strategy centers on developing cellular and cell-derived therapeutics, combined with proprietary minimally invasive delivery and navigation technologies designed to place treatment directly in the target tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai)) BioCardia’s history is rooted in regenerative medicine and cardiac intervention. Over time, the company built a portfolio around cell therapy programs and catheter-based delivery tools, and later adopted the BioCardia name following a reverse merger transaction. The business remains highly concentrated in the U.S., with core operations in Sunnyvale and a lean organization that includes clinical development, product development, regulatory, manufacturing, quality, finance, administration, and commercial support functions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/925741/000143774925009397/bcda20241231_10k.htm?utm_source=openai)) The company’s core pipeline is led by CardiAMP®, an autologous mononuclear cell therapy intended for ischemic heart failure with reduced ejection fraction. BioCardia also develops CardiALLO™, an investigational allogeneic “off-the-shelf” cell therapy platform, as well as the Helix™ biotherapeutic delivery system, a transendocardial catheter platform used to deliver therapeutic or diagnostic agents to the heart. In addition, the company’s Morph® DNA steerable introducer products support navigation and positioning during procedures. This integrated product stack is a key differentiator: BioCardia is not only developing a therapy, but also the procedural infrastructure needed to administer it. ([biocardia.com](https://www.biocardia.com/about-us/about-biocardia/id/1008?utm_source=openai)) From a competitive standpoint, BioCardia remains a specialty, development-stage name with limited commercial scale and a heavy reliance on clinical, regulatory, and financing milestones. Its target markets include ischemic heart failure and refractory angina, areas where treatment options remain constrained. In 2025 and 2026, the company highlighted late-stage CardiAMP HF data and continued discussions with the FDA and Japan’s PMDA. In March 2026, BioCardia reported that the FDA accepted its Helix pre-submission package, and in May 2026 it stated that the agency had aligned on possible clearance pathways for the delivery system, which could improve regulatory visibility over time. ([globenewswire.com](https://www.globenewswire.com/en/news-release/2025/03/31/3052241/0/en/biocardia-phase-3-cardiamp-hf-trial-of-novel-cardiac-cell-therapy-for-ischemic-heart-failure-shows-increased-survival-decreased-cardiac-events-and-improved-quality-of-life-at-two-y.html?utm_source=openai)) For investors, BioCardia is a high-risk, high-optional interest story: a micro-cap clinical biotherapy company with differentiated technology, a U.S. manufacturing and development base, and meaningful upside tied to trial outcomes, regulatory approvals, and eventual partnering or commercialization opportunities. ([biocardia.com](https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=256&utm_source=openai))